Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses

Cognitive impairment (CI) is common in α-synucleinopathies, i.e., Parkinson’s disease, Lewy bodies dementia, and multiple system atrophy. We summarize data from systematic reviews/meta-analyses on neuroimaging, neurophysiology, biofluid and genetic diagnostic/prognostic biomarkers of CI in α-synucle...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NPJ Parkinson's Disease Jg. 10; H. 1; S. 211 - 17
Hauptverfasser: Mantovani, Elisa, Martini, Alice, Dinoto, Alessandro, Zucchella, Chiara, Ferrari, Sergio, Mariotto, Sara, Tinazzi, Michele, Tamburin, Stefano
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 02.11.2024
Nature Publishing Group
Nature Portfolio
Schlagworte:
692/53/2421
692/53/2422
692/617/375/1718
692/699/375/1718
Alzheimer's disease
Artificial intelligence
Atrophy
Biomarkers
Biomedical and Life Sciences
Biomedicine
Cerebrospinal fluid
Cognitive ability
Dementia
Disease
Medical imaging
Meta-analysis
Neuroimaging
Neurology
Neuropathology
Neurophysiology
Neurosciences
ISSN:2373-8057, 2373-8057
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Cognitive impairment (CI) is common in α-synucleinopathies, i.e., Parkinson’s disease, Lewy bodies dementia, and multiple system atrophy. We summarize data from systematic reviews/meta-analyses on neuroimaging, neurophysiology, biofluid and genetic diagnostic/prognostic biomarkers of CI in α-synucleinopathies. Diagnostic biomarkers include atrophy/functional neuroimaging brain changes, abnormal cortical amyloid and tau deposition, and cerebrospinal fluid (CSF) Alzheimer’s disease (AD) biomarkers, cortical rhythm slowing, reduced cortical cholinergic and glutamatergic and increased cortical GABAergic activity, delayed P300 latency, increased plasma homocysteine and cystatin C and decreased vitamin B12 and folate, increased CSF/serum albumin quotient, and serum neurofilament light chain. Prognostic biomarkers include brain regional atrophy, cortical rhythm slowing, CSF amyloid biomarkers, Val66Met polymorphism, and apolipoprotein-E ε2 and ε4 alleles. Some AD/amyloid/tau biomarkers may diagnose/predict CI in α-synucleinopathies, but single, validated diagnostic/prognostic biomarkers lack. Future studies should include large consortia, biobanks, multi-omics approach, artificial intelligence, and machine learning to better reflect the complexity of CI in α-synucleinopathies.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2373-8057
2373-8057
DOI:10.1038/s41531-024-00823-x